Waters Corporation (WATERS CORP) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2000. Waters Corporation is the world's largest manufacturer of high performance liquid chromatography (HPLC) instruments and a leader in mass spectrometry (via Micromass) and thermal analysis (via TA Instruments). The company operates in the analytical instrument industry, serving life science, pharmaceutical, and industrial sectors.
Key Financial Metrics
| Metric | Q3 2000 | Q3 1999 | YTD 9M 2000 | YTD 9M 1999 |
|---|---|---|---|---|
| Net Sales | $194.1M | $171.1M | $570.0M | $503.7M |
| Gross Profit | $123.2M | $109.2M | $361.5M | $317.5M |
| Gross Margin | 63.5% | 63.8% | 63.4% | 63.0% |
| Operating Income | $51.4M | $41.5M | $143.7M | $118.0M |
| Net Income | $38.2M | $29.0M | $105.8M | $80.9M |
| Diluted EPS | $0.28 | $0.22 | $0.78 | $0.60 |
| Cash from Operations (9M) | $115.5M | |||
| Cash & Equivalents (End Period) | $23.2M | |||
| Total Debt (Current + Long Term) | $17.4M |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% year-over-year for both the quarter and the nine-month period. Excluding the adverse impact of a stronger U.S. dollar, organic growth was 18% for the quarter and 16% for the period.
- Profitability: Operating income rose 24% for the quarter and 22% for the nine-month period, driven by sales growth, volume leverage, and cost controls.
- Debt Reduction: The company significantly reduced its debt load, repaying $77.8 million in bank debt during the nine-month period. Total debt decreased from $95.3 million at year-end 1999 to $17.4 million at September 30, 2000.
- Currency Impact: A stronger U.S. dollar reduced reported sales growth by approximately 5 percentage points in the quarter due to the weakening Euro and British pound.
- Stock Split: A two-for-one stock split was executed in August 2000; all share and per-share data have been retroactively restated.
Outlook, Risks, and Unusual Items
- Guidance & Outlook: Management expects currency rates to continue presenting a translation challenge in Q4 2000 and 2001. Strong demand is noted in life sciences and mass spectrometry, particularly time-of-flight products for proteomics and drug discovery.
- Strategic Alliance: In June 2000, Waters formed an alliance with Variagenics, Inc., investing $7.5 million for equity and $3.0 million for a license to develop genetic variance reagent kits. Future milestone payments of up to $4 million are possible.
- Legal Proceedings: The company is involved in several patent disputes (Perkin-Elmer, Hewlett-Packard, Cohesive Technologies, Viscotek, and MDS/Sciex). Management believes it has meritorious arguments in all cases and does not expect any outcome to be material to the company.
- Accounting Changes: The company is evaluating the impact of new revenue recognition standards (SAB 101) and derivative accounting standards (SFAS 133), though no material impact is currently expected.
Investor Verification Checklist
- Currency Sensitivity: Verify the extent of exposure to the Euro and British pound, as currency translation significantly impacted reported growth.
- Debt Covenant Compliance: Confirm that the aggressive debt repayment ($77.8M) aligns with the company's liquidity strategy and does not constrain future capital expenditures.
- Legal Exposure: Monitor the status of the Perkin-Elmer appeal and the HP patent litigation, as these involve core product lines.
- Variagenics Investment: Track the progress of the Variagenics alliance and the potential for future milestone payments.
- Revenue Recognition: Review the final impact of SAB 101 implementation on future revenue reporting.